For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
38
views
94
references
 Top references
cited by
80
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
2 collections
    0
    shares
      173
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found

      American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).

          Methods

          A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID‐19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9‐point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings.

          Results

          Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID‐19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination.

          Conclusion

          These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID‐19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.

          Related collections

          Most cited references94

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

          Fei Zhou, Ting Yu, Ronghui Du … (2020)
          Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p<0·0001), and d-dimer greater than 1 μg/mL (18·42, 2·64–128·55; p=0·0033) on admission. Median duration of viral shedding was 20·0 days (IQR 17·0–24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days. Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
          Article 0 comments Cited 13434 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

            Chaomin Wu, Xiaoyan Chen, Yanping Cai … (2020)
            Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. Risk factors for the clinical outcomes of COVID-19 pneumonia have not yet been well delineated.
            Article 0 comments Cited 3635 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              OpenSAFELY: factors associated with COVID-19 death in 17 million patients

              Elizabeth J Williamson, Alex J Walker, Krishnan Bhaskaran … (2020)
              COVID-19 has rapidly impacted on mortality worldwide. 1 There is unprecedented urgency to understand who is most at risk of severe outcomes, requiring new approaches for timely analysis of large datasets. Working on behalf of NHS England we created OpenSAFELY: a secure health analytics platform covering 40% of all patients in England, holding patient data within the existing data centre of a major primary care electronic health records vendor. Primary care records of 17,278,392 adults were pseudonymously linked to 10,926 COVID-19 related deaths. COVID-19 related death was associated with: being male (hazard ratio 1.59, 95%CI 1.53-1.65); older age and deprivation (both with a strong gradient); diabetes; severe asthma; and various other medical conditions. Compared to people with white ethnicity, black and South Asian people were at higher risk even after adjustment for other factors (HR 1.48, 1.29-1.69 and 1.45, 1.32-1.58 respectively). We have quantified a range of clinical risk factors for COVID-19 related death in the largest cohort study conducted by any country to date. OpenSAFELY is rapidly adding further patients’ records; we will update and extend results regularly.
              Article 0 comments Cited 2915 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Jeffrey R. Curtis:
                ORCID: https://orcid.org/0000-0002-8907-8976
                jrcurtis@uabmc.edu
                Journal
                Journal ID (nlm-ta): Arthritis Rheumatol
                Journal ID (iso-abbrev): Arthritis Rheumatol
                Journal ID (doi): 10.1002/(ISSN)2326-5205
                Journal ID (publisher-id): ART
                Title: Arthritis & Rheumatology (Hoboken, N.j.)
                Publisher: John Wiley and Sons Inc. (Hoboken )
                ISSN (Print): 2326-5191
                ISSN (Electronic): 2326-5205
                Publication date (Electronic): 04 August 2021
                Publication date PMC-release: 04 August 2021
                Electronic Location Identifier: 10.1002/art.41928
                Affiliations
                [ 1 ] University of Alabama at Birmingham
                [ 2 ] Toronto Western Hospital Mount Sinai Hospital, and University of Toronto Toronto Ontario Canada
                [ 3 ] Louis Stokes Cleveland VA Medical Center MetroHealth Medical Center, and Case Western Reserve University Cleveland Ohio United States
                [ 4 ] VA North Texas Health Care System and University of Texas Southwestern Medical Center Dallas
                [ 5 ] Brigham and Women’s Hospital Boston Massachusetts United States
                [ 6 ] Hospital for Special Surgery and Weill Cornell Medicine New York New York United States
                [ 7 ] Cleveland Clinic Cleveland Ohio United States
                [ 8 ] Harpaz Herman Consultants Atlanta Georgia United States
                [ 9 ] CDC Atlanta Georgia United States
                [ 10 ] Duke University Durham North Carolina United States
                [ 11 ] American College of Rheumatology Atlanta Georgia United States
                [ 12 ] The Permanente Medical Group Union City California United States
                [ 13 ] University of Nebraska Medical Center and VA Nebraska–Western Iowa Health Care System Omaha
                Author notes
                [*] [* ]Address correspondence to Jeffrey R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, FOT 802, 510 20th Street South, Birmingham, AL 35294. Email: jrcurtis@ 123456uabmc.edu .
                Author information
                https://orcid.org/0000-0002-8907-8976
                https://orcid.org/0000-0003-0591-2976
                https://orcid.org/0000-0002-3225-8351
                https://orcid.org/0000-0001-7695-2022
                https://orcid.org/0000-0002-0897-2272
                Article
                Publisher ID: ART41928
                DOI: 10.1002/art.41928
                PMC ID: 8426685
                PubMed ID: 34346564
                SO-VID: 0c0709aa-395f-4c8f-8b39-6d6e598226d7
                Copyright © © 2021, American College of Rheumatology
                License:

                This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

                History
                Date received : 10 February 2021
                Date accepted : 10 March 2021
                Page count
                Figures: 0, Tables: 6, Pages: 16, Words: 14348
                Categories
                Subject: Full Length
                Subject: Full Length
                Custom metadata
                source-schema-version-number 2.0
                edited-state corrected-proof
                details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.7 mode:remove_FC converted:09.09.2021

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content173

                See all similar

                Cited by77

                See all cited by

                Most referenced authors1,960

                See all reference authors